Longitudinal change in dopamine transporter availability in idiopathic REM sleep behavior disorder
- PMID: 32989104
- DOI: 10.1212/WNL.0000000000010942
Longitudinal change in dopamine transporter availability in idiopathic REM sleep behavior disorder
Abstract
Objective: To elucidate longitudinal changes in the dopamine transporter (DAT) availability in association with the prodromal markers in idiopathic REM sleep behavior disorder (iRBD), we analyzed a longitudinal prospective iRBD cohort data.
Method: The study cohort consisted of patients with iRBD, individuals with Parkinson disease (PD), and healthy controls. All participants were evaluated for olfaction, neuropsychological tests, and the Movement Disorders Society-Unified Parkinson's Disease Rating Scale and underwent 18F-FP-CIT PET scans every 2 years. We calculated the DAT pattern by performing the principal component analysis of tracer uptakes in 6 striatal regions.
Result: DAT patterns in patients with iRBD with baseline hyposmia, constipation, and mild parkinsonian signs distributed toward the PD pattern and clearly distinguished from the healthy control pattern. The DAT pattern moved toward the PD pattern over time in some patients with iRBD during the follow-up, and baseline hyposmia was the only biomarker significantly associated with this change. Baseline PD pattern of DAT predicted 58% of disease converters (hazard ratio 4.95 [95% confidence interval 1.16-21.08]). The combination of hyposmia and baseline PD pattern of DAT predicted 67% of the conversion (hazard ratio 7.89 [confidence interval 1.85-33.69]). The estimated sample size required for a simulated neuroprotective clinical trial was 63 per group when the annual change of DAT pattern was used as an outcome in the subgroup with baseline DAT PD pattern and hyposmia, which is the smallest number reported so far.
Conclusion: Baseline and longitudinal monitoring of the DAT pattern can be a useful biomarker in identifying individuals with a high risk of disease conversion and in selecting the potential population for clinical trials in iRBD.
© 2020 American Academy of Neurology.
Comment in
-
Dopamine imaging in prodromal Parkinson disease trials: Ready for prime time?Neurology. 2020 Dec 8;95(23):1029-1030. doi: 10.1212/WNL.0000000000010957. Epub 2020 Sep 28. Neurology. 2020. PMID: 32989111 No abstract available.
Similar articles
-
FDG PET, dopamine transporter SPECT, and olfaction: Combining biomarkers in REM sleep behavior disorder.Mov Disord. 2017 Oct;32(10):1482-1486. doi: 10.1002/mds.27094. Epub 2017 Jul 22. Mov Disord. 2017. PMID: 28734065 Free PMC article.
-
Correlations between dopaminergic dysfunction and abnormal metabolic network activity in REM sleep behavior disorder.J Cereb Blood Flow Metab. 2020 Mar;40(3):552-562. doi: 10.1177/0271678X19828916. Epub 2019 Feb 10. J Cereb Blood Flow Metab. 2020. PMID: 30741074 Free PMC article. Clinical Trial.
-
Dopamine transporter imaging deficit predicts early transition to synucleinopathy in idiopathic rapid eye movement sleep behavior disorder.Ann Neurol. 2017 Sep;82(3):419-428. doi: 10.1002/ana.25026. Ann Neurol. 2017. PMID: 28833467
-
Parkinson disease and sleep: sleep-wake changes in the premotor stage of Parkinson disease; impaired olfaction and other prodromal features.Curr Neurol Neurosci Rep. 2013 Sep;13(9):373. doi: 10.1007/s11910-013-0373-0. Curr Neurol Neurosci Rep. 2013. PMID: 23881622 Review.
-
From Rapid Eye Movement Sleep Behavior Disorder to Parkinson's Disease: Possible Predictive Markers of Conversion.ACS Chem Neurosci. 2019 Feb 20;10(2):824-827. doi: 10.1021/acschemneuro.8b00388. Epub 2018 Oct 1. ACS Chem Neurosci. 2019. PMID: 30222303 Review.
Cited by
-
Mild behavioral impairment in idiopathic REM sleep behavior disorder and Lewy body disease continuum.J Neural Transm (Vienna). 2025 May;132(5):637-644. doi: 10.1007/s00702-024-02877-w. Epub 2025 Jan 9. J Neural Transm (Vienna). 2025. PMID: 39786627 Free PMC article.
-
Efficacy of 11C-2β-carbomethoxy-3β-(4-fluorophenyl) tropane positron emission tomography combined with 18F-fluorodeoxyglucose positron emission tomography in the diagnosis of early Parkinson disease: A protocol for systematic review and meta analysis.Medicine (Baltimore). 2020 Dec 18;99(51):e23395. doi: 10.1097/MD.0000000000023395. Medicine (Baltimore). 2020. PMID: 33371068 Free PMC article.
-
Associations of striatal dopamine transporter binding with motor and non-motor symptoms in early Parkinson's disease.Clin Transl Sci. 2023 Jun;16(6):1021-1038. doi: 10.1111/cts.13508. Epub 2023 Mar 23. Clin Transl Sci. 2023. PMID: 36915231 Free PMC article.
-
Longitudinal evolution of cortical thickness signature reflecting Lewy body dementia in isolated REM sleep behavior disorder: a prospective cohort study.Transl Neurodegener. 2023 May 22;12(1):27. doi: 10.1186/s40035-023-00356-y. Transl Neurodegener. 2023. PMID: 37217951 Free PMC article.
-
Clinical features and neurobiochemical mechanisms of olfactory dysfunction in patients with Parkinson disease.J Neurol. 2024 Apr;271(4):1959-1972. doi: 10.1007/s00415-023-12122-1. Epub 2023 Dec 27. J Neurol. 2024. PMID: 38151574
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical